Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PDX vs USPH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

USPH Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 8–2 Matrix Metrics)

USPH Overall Winner 6-Pillar Tally: PDX 0 – 5 USPH (1 Tie) Matrix Metrics: PDX 2 – 8 USPH

As of Nov 16, 2026, US Physical Therapy Inc (USPH) is the stronger overall head-to-head candidate over PIMCO Dynamic Income Strategy Fund (PDX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PDX carries a Unified Composite Score of 45.3/100 (HOLD) at $20.06 (N/M Forward P/E, N/A operating margin), whereas USPH carries 31.8/100 (SELL) at $99.55 (29.6x Forward P/E, 10.2% operating margin).

  • Composite vs. Pillar Nuance: While PDX currently prints a higher short-term Unified Composite Score (45.3/100 HOLD vs. USPH 31.8/100 SELL), USPH captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (10.2% vs. N/A operating margin) and revenue trajectory (+13.1% vs. N/A YoY).
  • Technical & Structure Timing Caution: PDX is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 40.7); meanwhile USPH trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 71.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PDX vs USPH
PDX NYSE
PIMCO Dynamic Income Strategy Fund
Institutional Equity
$20.06
-0.5% 1D
Market Cap $1.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.19β · 16% Vol
Unified Composite Score
45.3 / 100 HOLD
Tech 41.0 Fund 48.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -2.4%) with fading momentum, RSI 41
RSI-14: 40.7 · SMA20: $20.47 · SMA50: $20.59
USPH NYSE Head-to-Head Winner
US Physical Therapy Inc
Services-Health Services
$99.55
-0.05% 1D
Market Cap $1.5B
TTM Revenue $830M
Forward P/E 29.6x
Beta / 30D Vol 0.14β · 42% Vol
Unified Composite Score
31.8 / 100 SELL
Tech 50.0 Fund 25.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.2% over 20 days), RSI 72
RSI-14: 71.8 · SMA20: $91.84 · SMA50: $86.65

6-Pillar Scorecard Institutional Category Breakdown (PDX 0 – 5 USPH)

Columns: Metric · PDX · USPH
1. Valuation Multiples USPH
Forward P/E N/M 29.6x
Trailing P/E N/M 32.9x
PEG Ratio N/M 3.29x
EV / Revenue N/M 1.8x
2. Growth & Scale USPH
Revenue Growth (YoY) N/A +13.1%
Earnings Growth (YoY) N/A -56.5%
TTM Revenue (USD) N/A $830M
Market Cap $1.1B $1.5B
3. Profitability & Quality USPH
Gross Margin N/A 21.6%
Operating Margin N/A 10.2%
Net Profit Margin N/A 3.6%
Return on Equity (ROE) N/A 6.3%
4. Balance Sheet & Cash Flow USPH
Cash Generation (TTM) N/A $107M EBITDA
Cash Flow Margin N/A 12.9% EBITDA Mgn
Net Cash / Leverage N/A ROE $28.76 Book/Sh · 6.3% ROE
Dividend Yield None (0.00%) 1.86%
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 35.3% (<1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Markup
6. R&D & Supply-Chain Moat USPH
OpEx & R&D Intensity N/A 11.4% of Rev ($95M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PDX (2) vs USPH (8)
Institutional Metric PDX USPH Criterion Row Edge
Market Capitalization
Scale
$1.1B $1.5B Larger Scale USPH
Trailing P/E Ratio
Valuation
N/M 32.9x Lower Multiple USPH
Forward P/E Ratio
Valuation
N/M 29.6x Lower Multiple USPH
Revenue Growth (YoY)
Growth
N/A +13.1% Higher Growth USPH
Operating Margin (TTM)
Profitability
N/A 10.2% Higher Margin USPH
Net Profit Margin
Profitability
N/A 3.6% Higher Margin USPH
Return on Equity (ROE)
Capital Efficiency
N/A 6.3% Higher ROE USPH
52-Week Range Position
Momentum
42% ($18–$22) 95% ($58–$102) Stronger Trend USPH
Beta / 30D Volatility
Risk Regime
0.19β · 16% Vol 0.14β · 42% Vol Lower Realized Risk PDX
Unified Institutional Score
Composite Signal
45.3 / 100 (HOLD) 31.8 / 100 (SELL) Higher Composite PDX
Trailing 12M Revenue (USD)
Operating Scale
N/A $830M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 21.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 3.29x PEG · 1.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $107M EBITDA ($28.76 Book/Sh · 6.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon USPH +15.95 pp
PDX: +0.2% · USPH: +16.15%
3M Horizon USPH +34.98 pp
PDX: -7.69% · USPH: +27.29%
6M Horizon USPH +60.19 pp
PDX: -7.13% · USPH: +53.06%
1Y Horizon USPH +47.47 pp
PDX: -7.69% · USPH: +39.78%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PDX vs USPH. Trailing 12-month operating profitability (PDX N/A vs USPH 10.2%) and valuation multiples (PDX N/M vs USPH 29.6x Forward P/E) are benchmarked directly in Pillar 4 below.

PDX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
USPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$830M
Gross Margin21.6%
Op. Margin10.2%
ROE / Fwd P/E6.3% · 29.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PDX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PDX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
USPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 35.3%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact USPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PDX Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with $1.1B market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
USPH Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $1.5B market capitalization and 10.2% operating margin.
OpEx & R&D Reinvestment 11.4% of Rev ($95M)
90D Engineering Disclosures 0 Published

Investor FAQ PDX vs USPH Key Questions & Quantitative Answers

As of Nov 16, 2026, US Physical Therapy Inc (USPH) is the stronger overall head-to-head candidate over PIMCO Dynamic Income Strategy Fund (PDX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PDX carries a Unified Composite Score of 45.3/100 (HOLD) at $20.06 (N/M Forward P/E, N/A operating margin), whereas USPH carries 31.8/100 (SELL) at $99.55 (29.6x Forward P/E, 10.2% operating margin). Composite vs. Pillar Nuance: While PDX currently prints a higher short-term Unified Composite Score (45.3/100 HOLD vs. USPH 31.8/100 SELL), USPH captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (10.2% vs. N/A operating margin) and revenue trajectory (+13.1% vs. N/A YoY). Technical & Structure Timing Caution: PDX is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 40.7); meanwhile USPH trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 71.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

USPH leads the Growth & Scale pillar: PDX posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with USPH at +13.1% YoY revenue growth and -56.5% YoY earnings growth on $830M TTM revenue (21.6% gross margin, 10.2% operating margin). On trailing 12-month operating scale, PDX generates N/A in USD-normalized revenue versus $830M for USPH. In operating R&D and SG&A reinvestment, PDX deploys N/A (0 90-day corporate R&D disclosures) versus 11.4% of Rev ($95M) (0 disclosures) for USPH.

USPH screens cheaper on headline valuation multiples. PDX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas USPH trades at 29.6x Forward P/E, 32.9x Trailing P/E, 3.29x PEG, and 1.8x EV/Revenue (12.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PDX (N/A ROE) versus USPH (6.3% ROE) capital efficiency.

In options market volatility and institutional positioning, PDX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.19β · 16% Vol realized risk). By comparison, USPH carries 35.3% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 42% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.